Introduction
Evidence from both functional as well as ligand binding studies has supported the hypothesis that the effects of opioid drugs on the central nervous system are mediated via multiple receptors (Kosterlitz, 1985) . The development of highly selective ligands for opioid receptor subtypes has facilitated attempts to identify the receptors mediating specific opioid-induced responses. Although some controversy remains regarding the proper categorisation of naloxone-sensitive receptors, the available evidence strongly supports the existence of a putative p receptor, for which morphine is the prototypic ligand, a 5 receptor, which has a relative selectivity for peptides such as methionine and leucine enkephalin, and a K receptor, for which dynorphin A and related peptides appear to be the endogenous ligands. Although morphine and the opioid peptides are somewhat selective for the different receptor subtypes, the degree of such selectivity is often insufficient to permit the identification of the receptor involved in specific physiological responses. An additional complication from a physiological 'Author for correspondence. standpoint is that multiple receptor subtypes can often be found in the same brain region, and even on the same neurones (Williams & Zieglgansberger, 1981; Werz & Macdonald, 1983) .
In the central nervous system, considerable interest has focused on the actions of opioids in the hippocampus; in this brain region, morphine and opioid peptides have an excitatory effect that reflects the ability of opioids to inhibit the firing of inhibitory interneurones (Zieglgtinsberger et al., 1979; al., 1980; Lee et al., 1980; Nicoll et al., 1980; Robinson & Deadwyler, 1980 (EC, . Although several J-selective peptides, such as Met(O) 5 ol]enkephalin and morphiceptin, exhibit relatively high potencies (Gahwiler & Maurer, 1981; Bostock et al., 1984) , morphine itself is a relatively weak agonist (EC5O -3 gM; Robinson & Deadwyler, 1980; Dingledine, 1981; Valentino & Dingledine, 1982) .
In terms of the effects of c-selective agonists, the picture is even less clear. Dynorphin A (1-17) in subnanomolar concentrations can increase the population spike response (as do ;-and 6-agonists), but can also decrease the evoked response in higher concentrations via a naloxone-insensitive mechanism (Vidal et al., 1984) ; somewhat similar effects have been reported with other K agonists as well (Brookes & Bradley, 1984) . Bremazocine, another K agonist, has little effect by itself on cultured hippocampal neurones except in micromolar concentrations, but antagonizes the excitatory effects of the p-selective agonist FK 33-824 (Gahwiler & Maurer, 1981) . Ethylketocyclazocine, the prototypic K. ligand, has been reported to have little or no activity as either an agonist or an antagonist in the hippocampal slice preparation (Valentino & Dingledine, 1982) , but has weak antagonist properties on cultured hippocampal neurones (Gahwiler & Maurer, 1981 (North, 1986) . Although naloxone appears somewhat i-selective (Kosterlitz, 1985) , previous studies in the hippocampus have suggested that it has little or no ability to discriminate between responses to i-and 6-selective agonists (Valentino & Dingledine, 1982; Neumaier et al., 1986 (Gillan et al., 1981) . Bremazocine can also antagonize morphine analgesia, whereas U-50, 488H does not generally appear to exhibit opioid antagonism (Lahti et al., 1982; Von Voigtlander & Lewis, 1982) . For this reason, we have characterized responses to both U-50, 488H and bremazocine in the rat hippocampal slice preparation in order to determine whether multiple opioid receptors participate in responses to different agonists, and whether antagonistic effects at ;L-and 6-receptors are general properties of K-receptor agonists in this system.
Methods
Male Sprague-Dawley rats weighing between 150-250 g were obtained from Sasco (Omaha, Nebraska, U.S.A.). Hippocampal brain slices were prepared as described previously (Dunwiddie & Lynch, 1978; Yasuda et al., 1986) and immediately placed in chilled medium containing (mM) NaCI 124, KCI 4.9, KH2PO4 1.2, MgSO4 2.4, CaCI2 2.5, NaHCO3 25.6 and glucose 10 (pH 7.5) that was pregassed with 95% 02 and 5% CO2. Slices were transferred to a recording chamber maintained at 33 -34C, and perfused during the recording period with a constant flow of fresh oxygenated preheated medium at a rate of 2 ml min-'.
A total of 132 slices from 38 rats were examined. Twisted nichrome wire stimulation electrodes were placed under visual guidance in the stratum radiatum near the border of CA1-CA2, and monosynaptic responses were evoked in CAl by stimulation with monophasic 0.1 ms pulses of 6-30 V delivered to the slice at I min intervals. In every slice, the voltage was set so that the negative-going population spike response was approximately equal in magnitude to the amplitude of the positive field potential upon which it was superimposed. Evoked potentials were recorded with 2-3 MCI glass electrodes filled with 3 M NaCl placed in the CAl region under visual guidance.
Responses were recorded from the CAI pyramidal cell layer, and analysed on-line by a NOVA 3/12 computer. Drugs were made up in degassed deionized water at 100-1000 times the desired final concentration, then added to the flow of perfusion fluid with a calibrated syringe pump.
Slices were initially tested with a concentration of agonist that, on the basis of preliminary studies, was sufficient to evoke at least a 95% of maximal increase in the population spike response; the response to that concentration of drug was defined as the maximal response for that particular slice. Subsequently, the same slice was then tested with different concentra-tions of agonists and/or antagonists, and all subsequent responses expressed as a percentage of the initial test response. Moderate changes in the baseline between the pre-and post-drug periods were corrected for by the procedure illustrated in Figure 3 . Slices that manifested a high degree of shift in the baseline were not used. The potential degree of interference with these measures due to the development of tolerance during the initial test period was assessed by conducting control experiments in which the slice was tested repeatedly with the same concentration of agonist. Although slices tested with FK 33-824 did not show any tolerance according to this procedure, those tested with DPDPE showed a modest degree of tolerance with extended perfusion (as much as a 50% drop in the response during a 1 h perfusion). For this reason, the test periods with DPDPE were kept relatively brief, so that the maximum reduction in the second test response due to tolerance was less than 10%. When the effects of antagonists were examined on DPDPE responses, such responses were always compared to appropriate controls in which slices were perfused more than once with DPDPE without any antagonist present.
Hill plots of the raw data were used for the calculation of EC50 values, which correspond to the concentrations of agonist required to elicit 50% of maximal increases in the population spike response amplitude (Dunwiddie & Fredholm, 1984) , and demonstrated that this is an opioid-specific response. In the present experiments, we found that perfusion of hippocampal slices with either the L-selective agonist FK 33-824 or the 6-selective agonist DPDPE resulted in marked increases in the population spike response that were qualitatively indistinguishable from each other. An example of a response to FK 33-824 is illustrated in Figure 1 . The only significant difference that was observed between responses to DPDPE and FK 33-824 was that responses to DPDPE showed significant decrement during prolonged perfusion, whereas responses to FK 33-824 did not.
Although both the pt-and 6-selective agonists elicited marked increases in the evoked population spike response, perfusion of slices with K-selective agonists had no significant effect upon the evoked response. Slices were perfused for 10 min with 30 nM, I pM, and 1O LM bremazocine, and at the end of the test periods the mean ± s.e.mean population spike response as a percentage of the pre-drug control response was 93 ± 16, 99 ± 7.5, and 98 ± 13, respectively (n = 3, 6, and 6). U-50, 488H, another selective c-agonist, was also without effect upon the population spike amplitude (mean percentage of control response following 1 ILM was 98 ± 8.4, n = 9; response to I0 M was 99 ± 11, n = 6). None (Figure 2 ). In addition, when slices were pretreated with bremazocine, previously effective concentrations of agonists no longer induced changes in population Figure 3 ).
control; n = 6; P > 0.1), and only partially reduced the responses to DPDPE (mean response 75 ± 4.8% of controls, n = 11; P < 0.01). In order to characterize the mechanism underlying the antagonistic properties of bremazocine in greater detail, dose-response curves for the selective ps-and 6-agonists were determined, and the ability of bremazocine to induce shifts in the curves was examined. The protocol that was followed in these experiments is detailed in Figure 3 . Slices were initially tested with a sufficient concentration of agonist in order to determine the maximal opioid response for that slice, and the drug was washed out until the response amplitude returned to baseline. Subsequently, the slice was retested with increasing concentrations of agonist either in the presence or absence of bremazocine. The concentrations of bremazocine that were tested were determined on the basis of preliminary experiments to be those that induced an approximate 10 fold rightward shift in the dose-response relation. The results of these experiments are illustrated in Figure 4 . Bremazocine (Kosterlitz & Paterson, 1980; Kosterlitz, 1985) . In accordance with (Robinson & Deadwyler, 1980; Bostock et al., 1984 (Dunwiddie et al., 1982) . Moreover, Valentino & Dingledine (1982) (Kosterlitz, 1985) , one would expect U-50,488H to be approximately a 10 fold weaker antagonist than bremazocine; this was clearly not the case. In addition, if one K-agonist (bremazocine) was a gA-selective antagonist, and if this is an intrinsic property of all agonists that can occupy the K-receptor, then one would expect all K-agonists to show such selectivity. The fact that U-50, 488H was if anything a 6-selective antagonist is again inconsistent with this being a K-agonist-related effect.
The lack of direct actions of both bremazocine and U-50, 488H in the CAl region of hippocampus suggests that whatever the role of the K-receptor in hippocampus, the changes it elicits in cellular function are sufficiently subtle that they do not result in direct alterations in evoked population spike amplitude. On the other hand, these experiments provide strong support for the idea that multiple (perhaps p-and 6-) opioid receptors can induce increases in the evoked population spike response in hippocampus. Although the present studies do not indicate whether or not they do so via the same mechanisms or effects on the same cell types, there are numerous precedents for JA-and 6-receptors exerting parallel actions (Williams & Zieglgansberger, 1981; Werz & Macdonald, 1983) . The relative selectivity of bremazocine, which appears to differentiate between the receptors upon which DPDPE and FK 33-824 act, suggests that it may be an effective tool in characterizing subtypes in multiple opioid receptor systems.
